Brief: Celltrion Inc Says High Infliximab Trough Levels Are Associated With Low Risk Of Relapse When Switching To Subcutaneous Infliximab In Patients With Inflammatory Bowel Disease, Suggests New Data Presented At ECCO 2022 Virtual Congress
18/02/2022 11:40
Feb 18 (Reuters) - Celltrion Inc 068270.KS :
* HIGH INFLIXIMAB TROUGH LEVELS ARE ASSOCIATED WITH LOW RISK
OF
RELAPSE WHEN SWITCHING TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS
WITH INFLAMMATORY BOWEL DISEASE, SUGGESTS NEW DATA PRESENTED AT
ECCO 2022 VIRTUAL CONGRESS
Source text for Eikon: ID:nBw5DQwB8a
Further company coverage: 068270.KS
((reuters.briefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares